The REFLECT Trial - A Randomized Evaluation of the TriGuard HDH Embolic Deflection Device to Reduce the Impact of Cerebral Embolic Lesions after TransCatheter Aortic Valve Implantation
Sponsor: Keystone Heart
Enrolling: Male and Female Patients
IRB Number: AAAQ9626
U.S. Govt. ID: NCT02536196
Contact: Lauren Privitera: 212-342-3488 /
Additional Study Information: This is a research study designed to look at the safety and effectiveness of the TriGUARD 3 cerebral embolic protection device in patients undergoing transcatheter aortic valve implantation (TAVI). The purpose of the study is to assess whether the TriGUARD 3 can prevent death, stroke, more subtle signs of brain injury, and/or silent brain injury as measured by a magnetic resonance imaging (MRI) study of the brain.
This study is closed
Susheel Kodali, MD
Do You Qualify?
Are you 18 years or older Yes No
Is your physician planning an aortic valve procedure in the future Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Lauren Privitera